Immunotherapy of HPV-induced premalignant anogenital lesions and cervical cancer has made impressive progress. HPV as causative agent is targeted by prophylactic and therapeutic vaccination strategies. Preclinical and clinical studies have shown induction of natural and/or vaccine-induced immune responses. This review will summarize the status of vaccine development and clinical testing published since March 2003.For prophylactic vaccines there is first clinical evidence of effectivity (ie, 100
作者:Carola, Schreckenberger;Andreas M, Kaufmann
来源:Current opinion in oncology 2004 年 16卷 5期